Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002
We read with interest the recent editorial on selective cyclooxygenase 2 (COX-2) inhibitors and myocardial infarction1 that accompanied 3 case-control studies published in the same issue of the ARCHIVES.2- 4 The 3 studies suggest that patients treated with naproxen may have a decreased incidence of myocardial infarction compared with patients receiving other nonsteroidal anti-inflammatory drugs (NSAIDs) or those not receiving NSAIDs. The editorial concluded by saying that the findings of the Vioxx Gastrointestinal Outcomes Research (VIGOR) study,5 which demonstrated increased myocardial infarction with use of COX-2 inhibitors, are readily explained by the beneficial effect of naproxen rather than a detrimental effect of COX-2 inhibitors.
Mukherjee D, Nissen SE, Topol EJ. Lack of Cardioprotective Effect of Naproxen. Arch Intern Med. 2002;162(22):2637. doi: